Business Context and Reporting Period
Company: Impact BioMedical, Inc. (NYSE American: IBO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: The Company discovers and patents technologies for human healthcare and wellness, focusing on biopharmaceuticals, over-the-counter wellness offerings, and drug discovery. Key proprietary technologies include Linebacker (oncology/inflammation), Laetose (metabolic health), 3F (functional fragrances), and Equivir (antiviral). The Company operates through several subsidiaries and relies on licensing and strategic partnerships for commercialization.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | As of Sept 30, 2025 |
|---|---|---|---|
| Total Revenue | $18,000 | $25,000 | N/A |
| Net Loss | $(1,475,000) | $(17,105,000) | N/A |
| Operating Loss | $(948,000) | $(3,112,000) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $12,000 |
| Total Assets | N/A | N/A | $18,208,000 |
| Total Liabilities | N/A | N/A | $27,061,000 |
| Stockholders' Deficit | N/A | N/A | $(8,853,000) |
| Related Party Debt | N/A | N/A | $22,881,000 |
Note: Revenue is derived primarily from biotech retail sales of the Celios air purification system acquired in Q1 2025. The Net Loss for the nine-month period is significantly impacted by a non-cash fair value adjustment on related party debt.
Material Changes vs. Prior Period
- Liquidity Crisis: Cash and cash equivalents plummeted from $1,999,000 at December 31, 2024, to $12,000 at September 30, 2025. Net cash used in operating activities was $1,989,000 for the nine months ended September 30, 2025.
- Debt Escalation: The "Note payable, related party" balance increased from $8,878,000 (Dec 31, 2024) to $22,881,000 (Sept 30, 2025). This increase is largely due to a $13,210,000 non-cash fair value adjustment recognized in the nine-month period.
- Profitability Reversal: The Company reported a Net Loss of $17,105,000 for the nine months ended Sept 30, 2025, compared to Net Income of $2,363,000 for the same period in 2024. The 2024 income was driven by a $5,670,000 gain on the fair value of the related party note, whereas 2025 saw a corresponding loss.
- Expense Fluctuations:
- Professional Fees: Increased 177% year-over-year (nine months) to $868,000, driven by legal and consulting costs for business plan execution and M&A diligence.
- Sales & Marketing: Decreased 95% year-over-year to $22,000 due to cost-cutting measures.
- R&D: Decreased 40% year-over-year to $230,000 as the Company paused spending on certain in-development technologies.
- Asset Acquisition: In February 2025, the Company acquired assets from DSS PureAir (including Celios technology) for $1,150,000, paid via issuance of 545,024 shares of common stock.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that substantial doubt exists regarding the Company's ability to continue as a going concern within one year of the report date due to operating losses and negative cash flows. Management plans to monetize intellectual property and control costs to address this.
- Subsequent Events (Post-Sept 30, 2025):
- Debt Conversion: On October 16, 2025, the Company converted the entire $22,881,000 related party note payable into 31,939,778 shares of common stock.
- Preferred Stock Conversion: On October 16, 2025, 60,496,041 shares of Series A Convertible Preferred Stock were converted into common stock.
- Potential Merger: The Company entered into a Merger and Share Exchange Agreement with Dr Ashleys Limited, anticipated to close in Q1 2026.
- Internal Controls: The Company disclosed material weaknesses in internal controls over financial reporting that remained as of September 30, 2025, rendering disclosure controls ineffective.
- Revenue Uncertainty: The Company has not generated significant revenues historically. Future revenue depends on licensing milestones and royalties from partners (e.g., ProPhase Laboratories) and the commercialization of the newly acquired Celios technology.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance post-filing, given the balance of only $12,000 at quarter-end and the "Going Concern" warning.
- Debt Resolution: Confirm the final terms and share count impact of the October 2025 conversion of the $22.9M related party debt into equity.
- Merger Status: Monitor the progress of the proposed merger with Dr Ashleys Limited and the likelihood of closing in Q1 2026.
- Revenue Sustainability: Assess the commercial viability and sales trajectory of the Celios air purification system, which generated the only reported revenue ($25k for 9 months).
- Internal Controls: Review the remediation plan for the material weaknesses in internal controls disclosed in the 10-K and 10-Q.